Instituto de Investigación e Innovación en Ciencias Biomédicas (INiBICA)
Instituto de investigación
Eli Lilly and Company
Indianapolis, EE. UU.Publicaciones en colaboración con investigadores/as de Eli Lilly and Company (8)
2022
-
Patient-Reported Outcome Measures in Real-World Atopic Dermatitis Studies in Spain: A Systematic Review
Actas Dermo-Sifiliograficas, Vol. 113, Núm. 7, pp. 685-704
2016
-
Are there different predictors of analgesic response between antidepressants and anticonvulsants in painful diabetic neuropathy?
European Journal of Pain (United Kingdom), Vol. 20, Núm. 3, pp. 472-482
2014
-
Neuropathic pain phenotyping as a predictor of treatment response in painful diabetic neuropathy: Data from the randomized, double-blind, COMBO-DN study
Pain, Vol. 155, Núm. 10, pp. 2171-2179
2013
-
Structural and functional analysis of APOA5 mutations identifi ed in patients with severe hypertriglyceridemia
Journal of Lipid Research, Vol. 54, Núm. 3, pp. 649-661
2005
-
Safety and effectiveness of olanzapine in monotherapy: A multivariate analysis of a naturalistic study
Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 29, Núm. 6, pp. 944-951
-
Safety, effectiveness, and patterns of use of olanzapine in acute schizophrenia: A multivariate analysis of a large naturalistic study in the hospital setting
Medicina Clinica, Vol. 124, Núm. 13, pp. 481-486
2003
-
Safety and effectiveness of olanzapine versus conventional antipsychotics in the acute treatment of first-episode schizophrenic inpatients
Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 27, Núm. 3, pp. 473-481
-
Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia. A naturalistic study
European Neuropsychopharmacology, Vol. 13, Núm. 1, pp. 39-48